Table 3.
Results of the main clinical trials with anti-signaling lymphocytic activation molecule family 7 (SLAMF7) monoclonal antibody elotuzumab.
| Study | Phase | Number of Patients | Median Previous Line | Regimen | ORR | Median PFS (Months) |
Median OS (Months) |
|---|---|---|---|---|---|---|---|
| NCT00425347 [66] | I | 35 | 5 | Elo (0.5–20 mg/kg) | 0 | NA | NA |
| ELOQUENT-2 [67,68] | III | 321 | 2 | Elo-Rd vs. Rd | 79% vs. 66% | 19.4 vs.14.9 | 48 vs. 40 |
| ELOQUENT-3 [69] | II | 117 | 3 | Elo-Poma-dex vs. Pd | 53%vs.26% | 10.3 vs. 4.7 | NA |
| NCT00726869 [70] | I | 28 | 2 | Elo-V | 48% | 9.5 | NA |
| NCT01478048 [71] | II | 152 | NA | Elo-Vd vs. Vd | 66% vs. 63% | 9.7 vs. 6.9 | 2-year OS 73% vs. 66% |
Abbreviations: Elo, elotuzumab; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; d, dex, dexamethasone; R, lenalidomide; Poma, pomalidomide; V, bortezomib; NR, not reached; NA, not yet available.